Efficacy comparisons of solvent-based paclitaxel, liposomal paclitaxel, nanoparticle albumin-bound paclitaxel, and docetaxel after neoadjuvant systemic treatment in breast cancer

IF 4.7 4区医学 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Nanomedicine: Nanotechnology, Biology and Medicine Pub Date : 2023-09-17 DOI:10.1016/j.nano.2023.102707

Weiwei Zhang MSc , Ye Wang BMed , Jinzhi He BMed , Yinggang Xu MSc , Rui Chen MSc , Xinyu Wan BMed , Wenjie Shi BMed , Xiaofeng Huang MSc , Lu Xu MD , Jue Wang MD , Xiaoming Zha MD

{"title":"Efficacy comparisons of solvent-based paclitaxel, liposomal paclitaxel, nanoparticle albumin-bound paclitaxel, and docetaxel after neoadjuvant systemic treatment in breast cancer","authors":"Weiwei Zhang MSc , Ye Wang BMed , Jinzhi He BMed , Yinggang Xu MSc , Rui Chen MSc , Xinyu Wan BMed , Wenjie Shi BMed , Xiaofeng Huang MSc , Lu Xu MD , Jue Wang MD , Xiaoming Zha MD","doi":"10.1016/j.nano.2023.102707","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>There are four kinds of taxanes<span>: solvent-based paclitaxel<span><span> (Sb-P), liposomal paclitaxel (Lps-P), nanoparticle albumin-bound paclitaxel (Nab-P), and docetaxel. This study aims to retrospectively evaluate the efficacy of different taxanes on neoadjuvant </span>systemic treatment (NST) in breast cancer.</span></span></p></div><div><h3>Methods</h3><p>Patients who were diagnosed with breast cancer and had received integral NST from August 2013 to April 2022 were enrolled. The efficacy was divided into total pathological complete response (total-pCR), breast pathological complete response (breast-pCR), and axillary pathological complete response (axillary-pCR) for in-depth analysis and discussion.</p></div><div><h3>Results</h3><p>The choice of taxane was an independent risk factor for total-pCR and breast-pCR rates. The highest total-pCR and breast-pCR rates were found in the Nab-P group. The difference was not significant among all the taxanes in the axillary-pCR rate.</p></div><div><h3>Conclusion</h3><p>Nab-P significantly improved the total-pCR and breast-pCR rates. It should be the first choice among taxanes in NST for breast cancer.</p></div>","PeriodicalId":396,"journal":{"name":"Nanomedicine: Nanotechnology, Biology and Medicine","volume":"54 ","pages":"Article 102707"},"PeriodicalIF":4.7000,"publicationDate":"2023-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanomedicine: Nanotechnology, Biology and Medicine","FirstCategoryId":"1","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1549963423000588","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

There are four kinds of taxanes: solvent-based paclitaxel (Sb-P), liposomal paclitaxel (Lps-P), nanoparticle albumin-bound paclitaxel (Nab-P), and docetaxel. This study aims to retrospectively evaluate the efficacy of different taxanes on neoadjuvant systemic treatment (NST) in breast cancer.

Methods

Patients who were diagnosed with breast cancer and had received integral NST from August 2013 to April 2022 were enrolled. The efficacy was divided into total pathological complete response (total-pCR), breast pathological complete response (breast-pCR), and axillary pathological complete response (axillary-pCR) for in-depth analysis and discussion.

Results

The choice of taxane was an independent risk factor for total-pCR and breast-pCR rates. The highest total-pCR and breast-pCR rates were found in the Nab-P group. The difference was not significant among all the taxanes in the axillary-pCR rate.

Conclusion

Nab-P significantly improved the total-pCR and breast-pCR rates. It should be the first choice among taxanes in NST for breast cancer.

Abstract Image

查看原文本刊更多论文

溶剂型紫杉醇、脂质体紫杉醇、纳米颗粒白蛋白结合紫杉醇和多西紫杉醇在乳腺癌新辅助全身治疗后的疗效比较

目的紫杉醇类有溶剂型紫杉醇(Sb-P)、脂质体紫杉醇(Lps-P)、纳米颗粒白蛋白结合紫杉醇(nabp)和多西紫杉醇四种。本研究旨在回顾性评价不同紫杉烷类药物对乳腺癌新辅助全身治疗(NST)的疗效。方法纳入2013年8月至2022年4月期间诊断为乳腺癌并接受过整体NST治疗的患者。将疗效分为总病理完全缓解(total- pcr)、乳腺病理完全缓解(breast- pcr)和腋窝病理完全缓解(axillary- pcr)进行深入分析和讨论。结果紫杉烷的选择是总pcr率和乳房pcr率的独立危险因素。Nab-P组的total-pCR和breast-pCR率最高。各紫杉烷类的腋窝pcr率差异不显著。结论nab -p可显著提高总pcr率和乳房pcr率。它应该是乳腺癌NST紫杉烷类药物的首选。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nanomedicine: Nanotechnology, Biology and Medicine 医学-纳米科技

CiteScore

8.10

自引率

3.60%

发文量

104

审稿时长

4.6 months

期刊介绍： Nanomedicine: Nanotechnology, Biology and Medicine (NBM) is an international, peer-reviewed journal presenting novel, significant, and interdisciplinary theoretical and experimental results related to nanoscience and nanotechnology in the life and health sciences. Content includes basic, translational, and clinical research addressing diagnosis, treatment, monitoring, prediction, and prevention of diseases.